Drugs / Iparomlimab/Tuvonralimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07232654 | Nov 2025 → Nov 2027 expected | cervical carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iparomlimab/Tuvonralimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07232654 ↗ |
| Known as | QL1706 | “Iparomlimab/Tuvonralimab Injection (QL1706, a Bifunctional Mabpair Product of Anti-PD-1 and Anti-CTLA-4 Antibodies)” NCT07232654 ↗ |
| Modality | Monoclonal antibody | “a Bifunctional Mabpair Product of Anti-PD-1 and Anti-CTLA-4 Antibodies” NCT07232654 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT07232654 ↗ |